- Poster presentation
- Open access
- Published:
P005. Efficacy Type-A Botulinum toxin treatment in a multidisciplinary setting for chronic headache
The Journal of Headache and Pain volume 16, Article number: A185 (2015)
Background
Type-A botulinum toxin (BoNTA) therapy has emerged as an effective treatment for chronic headache (CH) [1]. No conclusive data exists about BoNTA efficacy in CH comorbid with anxiety and depression disorders. Our open prospective study aimed to evaluate CH BoNTA treatment efficacy regarding clinical and psychopathological variables in a multidisciplinary setting.
Materials and methods
We treated 32 CH patients (8 males; 24 females; 44.76±11.23 mean age) with 190-units BoNTA injections. Sessions took place from January 2014 to June 2015 once every 3 months; patients received headache education; at the baseline (T0) and at the final follow-up (T1) patients completed a headache diary, pain Numerical Rating Scale (NRS), Migraine Disability Assessment (MIDAS), Zung Self-Rating Anxiety Scale (SAS) and Zung Self-Rating Depression Scale (SDS). We considered patients responders if they had > 50% reduction in headache frequency and/or pain intensity compared with baseline. Using SOFA Statistics 1.4.4 software, we calculated descriptive indicators and evaluated treatment effect using paired-samples Student's t-test on clinical and psychosocial variables between T0 and T1. We set p < 0.05 as threshold of statistical significance.
Results
At T0 headache frequency (M±DS) was 23.71±5.38 headache days/month; NRS score was 9.10±0.94; MIDAS score was 57.59±24.72; SAS score was 48.38±12.16; SDS score was 46.68±14.31. At T1 headache frequency (M±DS) was 9.14±8.31 headache days/month; NRS score was 6.33±2.33; MIDAS score was 21.517±20.19; SAS score was 39.38±9.19; SDS score was 36.01±10.32. Twenty-one patients (65.25%) showed psychopathological comorbidity. We observed response to treatment in 23 patients (71.87%) with a statistically significant treatment effect on headache frequency (t = 8.539; p < 0.001), pain intensity (t = 5.451; p < 0.001), disability (t = 5.701; p < 0.001), anxiety (t = 3.457; p < 0.005) and depression (t = 2.59; p < 0.05).
Conclusions
Our data support that BoNTA in a multidisciplinary setting is an effective treatment for chronic headache, potentially addressing pain-related affective disorders. Further developments of our study could evaluate the effectiveness of enhanced psychological interventions, such as stress management, as a complement to the biomedical treatment.
Written informed consent to publish was obtained from the patient(s).
References
Cairns BE, Gazerani P: Botulinum neurotoxin A for chronic migraine headaches: does it work and how?. Pain Manag. 2014, 4 (6): 377-380. 10.2217/pmt.14.30.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Vescio, G., Costa, A., Squillace, A. et al. P005. Efficacy Type-A Botulinum toxin treatment in a multidisciplinary setting for chronic headache. J Headache Pain 16 (Suppl 1), A185 (2015). https://doi.org/10.1186/1129-2377-16-S1-A185
Published:
DOI: https://doi.org/10.1186/1129-2377-16-S1-A185